Orion Porfolio Solutions LLC lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 14.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 161,401 shares of the company's stock after purchasing an additional 19,883 shares during the period. Orion Porfolio Solutions LLC's holdings in AstraZeneca were worth $12,383,000 as of its most recent filing with the SEC.
A number of other hedge funds have also bought and sold shares of AZN. Cibc World Market Inc. lifted its position in shares of AstraZeneca by 21.5% in the 3rd quarter. Cibc World Market Inc. now owns 64,421 shares of the company's stock worth $4,942,000 after buying an additional 11,398 shares during the last quarter. TD Asset Management Inc lifted its holdings in AstraZeneca by 20.0% in the third quarter. TD Asset Management Inc now owns 1,089,612 shares of the company's stock worth $83,595,000 after acquiring an additional 181,273 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its stake in AstraZeneca by 111.6% in the third quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company's stock valued at $5,113,000 after acquiring an additional 35,148 shares during the period. AMG National Trust Bank grew its holdings in shares of AstraZeneca by 20.4% during the third quarter. AMG National Trust Bank now owns 42,983 shares of the company's stock valued at $3,298,000 after purchasing an additional 7,289 shares during the last quarter. Finally, Oxbow Advisors LLC raised its position in shares of AstraZeneca by 96.2% during the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company's stock worth $5,953,000 after purchasing an additional 38,043 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
AZN has been the subject of a number of analyst reports. Weiss Ratings restated a "buy (b)" rating on shares of AstraZeneca in a research report on Wednesday, January 21st. Morgan Stanley restated an "overweight" rating and set a $103.00 price target on shares of AstraZeneca in a research report on Wednesday, December 3rd. Citigroup assumed coverage on shares of AstraZeneca in a research report on Tuesday, January 27th. They issued a "buy" rating on the stock. Barclays reissued an "overweight" rating on shares of AstraZeneca in a research note on Tuesday, January 6th. Finally, Guggenheim reaffirmed a "buy" rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $95.75.
Check Out Our Latest Stock Analysis on AZN
AstraZeneca Stock Down 1.9%
Shares of AZN stock opened at $197.74 on Friday. AstraZeneca PLC has a 1 year low of $122.48 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The business's fifty day moving average is $144.68 and its 200-day moving average is $105.45. The stock has a market cap of $306.68 billion, a PE ratio of 65.69, a price-to-earnings-growth ratio of 1.59 and a beta of 0.32.
AstraZeneca Dividend Announcement
The firm also recently announced a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be issued a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date is Friday, February 20th. AstraZeneca's dividend payout ratio (DPR) is presently 66.26%.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca's operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.
The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astrazeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrazeneca wasn't on the list.
While Astrazeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
